英文摘要 |
Substantial reports showed the evidenced-based effect of transfusion of leuko-reduced platelet concentrates (LRPC) including reduction of non-hemolytic febrile transfusion adverse reaction (NHFTR), CMV infection and prevention of occurrence of platelet transfusion refractoriness. Therefore, LRPC rather than platelet concentrates can improve transfusion safety definitely. Cost evaluation revealed that using LRPC can reduce total fee in dealing with NHFTR. In addition, another study showed that transfusion of LRPC can decrease the cost of management of platelet transfusion refractoriness dramatically. In this moment, we call for releasing or completely eliminating the limitation on the use of LRPC to create a win-win situation in Taiwan. |